Incyte Corp (NASDAQ:INCY)
| 99.36 Delayed Data As of May 22 |  +0.68 / +0.69%Today’s Change | 62.48 Today|||52-Week Range 104.81 | +13.79% Year-to-Date |
Latest INCY News | Press Releases
| Why Gilead's Remdesivir Might Not Be the Mega-Moneymaker Some Think It Will Be May 17 / MotleyFool.com - Paid Partner Content | Why Geron Stock Soared 23.4% Today May 15 / MotleyFool.com - Paid Partner Content |
Today’s Trading
| Previous close | 98.68 |
| Today’s open | 97.72 |
| Day’s range | 97.53 - 101.75 |
| Volume | 118,564 |
| Average volume (3 months) | 1,864,504 |
| Market cap | $21.6B |
Data as of 6:55pm ET, 05/22/2020
Growth & Valuation
| Earnings growth (last year) | +299.90% |
| Earnings growth (this year) | -160.78% |
| Earnings growth (next 5 years) | +32.00% |
| Revenue growth (last year) | +14.71% |
| P/E ratio | NM |
| Price/Sales | 8.80 |
| Price/Book | 8.27 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| ALXNAlexion Pharmaceutic... | +0.42 | +0.42% |
| SGENSeattle Genetics Inc | +1.58 | +1.02% |
| ALNYAlnylam Pharmaceutic... | -1.44 | -1.02% |
| GLPGGalapagos NV | -3.57 | -1.75% |
Data as of 4:00pm ET, 05/22/2020
Financials
| Next reporting date | August 4, 2020 |
| EPS forecast (this quarter) | $0.59 |
| Annual revenue (last year) | $2.2B |
| Annual profit (last year) | $446.9M |
| Net profit margin | 20.70% |
Profile
Sector Health Technology |
Industry Biotechnology |
No executives to display |
Corporate headquarters Wilmington, Delaware |
Forecasts
